The United States Patent and Trademark Office (USPTO) has issued patent US12583841B2 for a novel tetrahydropyrrolocyclic compound developed by Breakthrough Pharmaceuticals Inc. This compound, represented by formula (I), is intended for use as a selective orexin-2 (OX-2) receptor antagonist and is specifically indicated for the preparation of drugs to treat insomnia and depression. The patent filing date was January 27, 2022, with the grant date set for March 24, 2026.

This patent grant signifies the protection of intellectual property for a new chemical entity and its therapeutic applications. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it is crucial for pharmaceutical companies and drug manufacturers to be aware of this patent. Companies operating in the insomnia and depression treatment space, particularly those researching orexin receptor antagonists, should review the patent claims to ensure their own research and development activities do not infringe upon Breakthrough Pharmaceuticals Inc.'s intellectual property rights. No immediate compliance actions are required by this patent grant itself, but it necessitates careful monitoring of the patent landscape for competitive and licensing considerations.